{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:46Z","timestamp":1786982146217,"version":"build-2736575974"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s11934-018-0800-5","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T04:02:32Z","timestamp":1526529752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Contemporary Review of Peyronie\u2019s Disease Treatment"],"prefix":"10.1007","volume":"19","author":[{"given":"Edward","family":"Capoccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,17]]},"reference":[{"key":"800_CR1","first-page":"423","volume":"1","author":"F Peyronie De la","year":"1743","unstructured":"De la Peyronie F. Sur quelques obstacles quis opposent a l ejaculation naturelle de la semence. Mem Acad Roy Chir. 1743;1:423\u201334.","journal-title":"Mem Acad Roy Chir"},{"key":"800_CR2","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/ajcp\/45.6.670","volume":"45","author":"BH Smith","year":"1966","unstructured":"Smith BH. Peyronie\u2019s disease. Am J Clin Pathol. 1966;45:670\u20138.","journal-title":"Am J Clin Pathol"},{"key":"800_CR3","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1111\/j.1743-6109.2008.00883.x","volume":"5","author":"R Rosen","year":"2008","unstructured":"Rosen R, Catania J, Lue T, Althof S, Henne J, Hellstrom W, et al. Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med. 2008;5:1977\u201384.","journal-title":"J Sex Med"},{"issue":"7","key":"800_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1046\/j.1464-4096.2001.02436.x","volume":"88","author":"U Schwarzer","year":"2001","unstructured":"\u2022 Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie\u2019s disease: results of a large survey. BJU Int. 2001;88(7):727\u201330. This was the first large cross-sectional study evaluating the prevalence of PD. The results helped demonstrate how PD is more widespread than previously thought.","journal-title":"BJU Int"},{"key":"800_CR5","first-page":"61","volume":"8","author":"KA Ostrowski","year":"2016","unstructured":"Ostrowski KA, Gannon JR, Walsh TJ. A review of the epidemiology and treatment of Peyronie's disease. Res Rep Urol. 2016;8:61\u201370.","journal-title":"Res Rep Urol."},{"issue":"1","key":"800_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.21037\/tau.2016.11.01","volume":"6","author":"J Campbell","year":"2017","unstructured":"Campbell J, Alzubaidi R. Understanding the cellular basis and pathophysiology of Peyronie's disease to optimize treatment for erectile dysfunction. Transl Androl Urol. 2017;6(1):46\u201359.","journal-title":"Transl Androl Urol"},{"issue":"3","key":"800_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.aju.2013.06.006","volume":"11","author":"AI El-Sakka","year":"2013","unstructured":"El-Sakka AI, Salabas E, Din\u00e7er M, Kadioglu A. The pathophysiology of Peyronie\u2019s disease. Arab Journal of Urology. 2013;11(3):272\u20137.","journal-title":"Arab Journal of Urology"},{"issue":"3","key":"800_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.5534\/wjmh.2013.31.3.183","volume":"31","author":"EJ Shaw","year":"2013","unstructured":"Shaw EJ, Mitchell GC, Tan RB, Sangkum P, Hellstrom WJ. The non-surgical treatment of peyronie disease: 2013 update. World J Mens Health. 2013;31(3):183\u201392.","journal-title":"World J Mens Health"},{"issue":"7","key":"800_CR9","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01850.x","volume":"7","author":"D Ralph","year":"2010","unstructured":"Ralph D, Gonzalez-cadavid N, Mirone V, et al. The management of Peyronie\u2019s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7(7):2359\u201374.","journal-title":"J Sex Med"},{"issue":"3","key":"800_CR10","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","volume":"194","author":"A Nehra","year":"2015","unstructured":"\u2022 Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie's Disease: AUA Guideline. J Urol. 2015;194(3):745\u201353. A systematic review of the literature regarding the diagnosis and treatment of PD. Based on the review, guideline statements were created to help Urologists make evidence based decisions when treating patients with PD.","journal-title":"J Urol"},{"key":"800_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/00007611-194802000-00017","volume":"41","author":"WW Scott","year":"1948","unstructured":"Scott WW, Scardino PA. A new concept in the treatment of Peyronie\u2019s disease. South Med J. 1948;41:173\u20137.","journal-title":"South Med J"},{"issue":"5","key":"800_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/sj.ijir.3900880","volume":"14","author":"SC Sikka","year":"2002","unstructured":"Sikka SC, Hellstrom WJ. Role of oxidative stress and antioxidants in Peyronie\u2019s disease. Int J Impot Res. 2002;14(5):353\u201360.","journal-title":"Int J Impot Res"},{"issue":"1","key":"800_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.2047-2927.2012.00007.x","volume":"1","author":"G Paulis","year":"2013","unstructured":"Paulis G, Brancato T, D'ascenzo R, et al. Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases. Andrology. 2013;1(1):120\u20138.","journal-title":"Andrology"},{"key":"800_CR14","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0022-5347(17)66108-1","volume":"81","author":"CJ Zarafonetis","year":"1959","unstructured":"Zarafonetis CJ, Horrax TM. Treatment of Peyronie's disease with potassium Para-aminobenzoate (potaba). J Urol. 1959;81:770\u20132.","journal-title":"J Urol"},{"issue":"12","key":"800_CR15","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1111\/j.1743-6109.2008.00918.x","volume":"5","author":"J Roy","year":"2008","unstructured":"Roy J, Carrier S. Acute hepatitis associated with treatment of Peyronie's disease with potassium Para-aminobenzoate (Potaba). J Sex Med. 2008;5(12):2967\u20139.","journal-title":"J Sex Med"},{"issue":"4","key":"800_CR16","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","volume":"47","author":"W Weidner","year":"2005","unstructured":"Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530\u20135.","journal-title":"Eur Urol"},{"issue":"1","key":"800_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2174\/187152812798889321","volume":"11","author":"G Paulis","year":"2012","unstructured":"Paulis G, Brancato T. Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic \u201crationale\u201d and related emerging treatment strategies. Inflamm Allergy Drug Targets. 2012;11(1):48\u201357.","journal-title":"Inflamm Allergy Drug Targets"},{"key":"800_CR18","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1464-410X.1992.tb15836.x","volume":"70","author":"DJ Ralph","year":"1992","unstructured":"Ralph DJ, Brooks MD, Bottazzo GF, et al. The treatment of Peyronie's disease with tamoxifen. Br J Urol. 1992;70:648\u201351. \n                      https:\/\/doi.org\/10.1111\/j.1464-410X.1992.tb15836\n                      \n                    .","journal-title":"Br J Urol"},{"issue":"6","key":"800_CR19","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/S0022-5347(05)68087-1","volume":"162","author":"C Teloken","year":"1999","unstructured":"Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol. 1999;162(6):2003\u20135.","journal-title":"J Urol"},{"issue":"6","key":"800_CR20","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/S0022-5347(05)68868-4","volume":"161","author":"AI El-sakka","year":"1999","unstructured":"El-sakka AI, Bakircioglu ME, Bhatnagar RS, Yen TS, Dahiya R, Lue TF. The effects of colchicine on a Peyronie\u2019s-like condition in an animal model. J Urol. 1999;161(6):1980\u20133.","journal-title":"J Urol"},{"issue":"3","key":"800_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","volume":"16","author":"MR Safarinejad","year":"2004","unstructured":"Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004;16(3):238\u201343.","journal-title":"Int J Impot Res"},{"issue":"6","key":"800_CR22","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1046\/j.1464-410X.2003.04134.x","volume":"91","author":"RM Prieto castro","year":"2003","unstructured":"Prieto castro RM, Leva vallejo ME, Regueiro lopez JC, Anglada curado FJ, Alvarez kindelan J, Requena tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int. 2003;91(6):522\u20134.","journal-title":"BJU Int"},{"issue":"1","key":"800_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2005.02.053","volume":"107","author":"LA Cal\u00f2","year":"2006","unstructured":"Cal\u00f2 LA, Pagnin E, Davis PA, Semplicini A, Nicolai R, Calvani M, et al. Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol. 2006;107(1):54\u201360.","journal-title":"Int J Cardiol"},{"issue":"1","key":"800_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1046\/j.1464-410x.2001.02241.x","volume":"88","author":"G Biagiotti","year":"2001","unstructured":"Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int. 2001;88(1):63\u20137.","journal-title":"BJU Int"},{"issue":"4 Pt 1","key":"800_CR25","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.juro.2007.05.162","volume":"178","author":"MR Safarinejad","year":"2007","unstructured":"Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol. 2007;178(4 Pt 1):1398\u2013403.","journal-title":"J Urol"},{"issue":"4","key":"800_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.niox.2003.12.002","volume":"9","author":"EG Valente","year":"2003","unstructured":"Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9(4):229\u201344.","journal-title":"Nitric Oxide"},{"issue":"1","key":"800_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1743-6109.2011.02519.x","volume":"9","author":"MR Abern","year":"2012","unstructured":"Abern MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's disease. J Sex Med. 2012;9(1):288\u201395.","journal-title":"J Sex Med"},{"issue":"3","key":"800_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000237979","volume":"27","author":"RS Griffith","year":"1981","unstructured":"Griffith RS, Delong DC, Nelson JD. Relation of arginine-lysine antagonism to herpes simplex growth in tissue culture. Chemotherapy. 1981;27(3):209\u201313.","journal-title":"Chemotherapy"},{"issue":"2","key":"800_CR29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/aja.2010.117","volume":"13","author":"JF Smith","year":"2011","unstructured":"Smith JF, Shindel AW, Huang YC, Clavijo RI, Flechner L, Breyer BN, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie's disease. Asian J Androl. 2011;13(2):322\u20135.","journal-title":"Asian J Androl."},{"issue":"3","key":"800_CR30","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1111\/bju.13063","volume":"115","author":"MR Safarinejad","year":"2015","unstructured":"Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. Retraction statement: a double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease. BJU Int. 2015;115(3):E10.","journal-title":"BJU Int"},{"issue":"2","key":"800_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/gut.50.2.241","volume":"50","author":"C Raetsch","year":"2002","unstructured":"Raetsch C, Jia JD, Boigk G, et al. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut. 2002;50(2):241\u20137.","journal-title":"Gut"},{"issue":"4","key":"800_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.niox.2003.12.002","volume":"9","author":"EG Valente","year":"2003","unstructured":"Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie\u2019s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9(4):229\u201344.","journal-title":"Nitric Oxide"},{"issue":"2","key":"800_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1365-2605.2011.01226.x","volume":"35","author":"A Palmieri","year":"2012","unstructured":"Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012;35(2):190\u20135.","journal-title":"Int J Androl"},{"issue":"5","key":"800_CR34","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1097\/01.ju.0000158664.00107.07","volume":"173","author":"RL Talbert","year":"2005","unstructured":"Talbert RL, Easterling WJ, Fitch W. Re: transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. 2005;173(5):1830.","journal-title":"J Urol"},{"key":"800_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/ijir.2015.22","volume":"28","author":"J Twidwell","year":"2015","unstructured":"Twidwell J, Levine LA. Topical treatment for acute phase Peyronie\u2019s disease utilizing a new gel, H-100: a randomized, prospective, placebo controlled pilot study. Int J Impot Res. 2015;28:41\u20135. \n                      https:\/\/doi.org\/10.1038\/ijir.2015.22\n                      \n                    .","journal-title":"Int J Impot Res"},{"key":"800_CR36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1743-6109.2006.00417.x","volume":"4","author":"WP Fitch 3rd","year":"2007","unstructured":"Fitch WP 3rd, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study. J Sex Med. 2007;4:477\u201384.","journal-title":"J Sex Med"},{"issue":"5","key":"800_CR37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0022-4804(90)90197-A","volume":"49","author":"RC Lee","year":"1990","unstructured":"Lee RC, Ping JA. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res. 1990;49(5):463\u20136.17367443.","journal-title":"J Surg Res"},{"issue":"2","key":"800_CR38","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1743-6109.2006.00417.x","volume":"4","author":"WP Fitch","year":"2007","unstructured":"Fitch WP, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study. J Sex Med. 2007;4(2):477\u201384.","journal-title":"J Sex Med"},{"issue":"5","key":"800_CR39","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1097\/01.ju.0000056153.47716.d0","volume":"169","author":"LA Levine","year":"2003","unstructured":"Levine LA, Estrada CR, Shou W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J Urol. 2003;169(5):1775\u20138.","journal-title":"J Urol"},{"issue":"3","key":"800_CR40","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.juro.2006.10.065","volume":"177","author":"JM Greenfield","year":"2007","unstructured":"Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie\u2019s disease: a double-blind, placebo controlled trial. J Urol. 2007;177(3):972\u20135.","journal-title":"J Urol"},{"key":"800_CR41","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0022-5347(05)64691-5","volume":"168","author":"LA Levine","year":"2002","unstructured":"Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie\u2019s disease. J Urol. 2002;168:621\u20135.","journal-title":"J Urol"},{"issue":"3","key":"800_CR42","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","volume":"41","author":"M Shirazi","year":"2009","unstructured":"Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie\u2019s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009;41(3):467\u201371.","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"800_CR43","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/sj.ijir.3900917","volume":"14","author":"LA Levine","year":"2002","unstructured":"Levine LA, Estrada CR. Intralesional verapamil for the treatment of Peyronie\u2019s disease: a review. Int J Impot Res. 2002;14(5):324\u20138.","journal-title":"Int J Impot Res"},{"key":"800_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ijir.2011.45","volume":"24","author":"SM Larsen","year":"2012","unstructured":"Larsen SM, Levine LA. Review of non-surgical treatment options for Peyronie\u2019s disease. Int J Impot Res. 2012;24:1\u201310.","journal-title":"Int J Impot Res"},{"issue":"1","key":"800_CR45","first-page":"52","volume":"16","author":"A Demey","year":"2006","unstructured":"Demey A, Chevallier D, Bondil P, Toubol J, Amiel J. Is intracavernosal corticosteroid infiltration really useless in Peyronie\u2019s disease? Prog Urol. 2006;16(1):52\u20137.","journal-title":"Prog Urol"},{"issue":"2","key":"800_CR46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3109\/00365599109024539","volume":"25","author":"MR Duncan","year":"1991","unstructured":"Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, \u2212beta and -gamma. Scand J Urol Nephrol. 1991;25(2):89\u201394.","journal-title":"Scand J Urol Nephrol"},{"issue":"1","key":"800_CR47","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","volume":"176","author":"WJ Hellstrom","year":"2006","unstructured":"Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie\u2019s disease. J Urol. 2006;176(1):394\u20138.","journal-title":"J Urol"},{"key":"800_CR48","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.juro.2013.05.022","volume":"190","author":"LW Trost","year":"2013","unstructured":"Trost LW, Ates E, Powers M, Sikka S, Hellstrom WJG. Outcomes of intralesional interferon-\u03b12B for the treatment of Peyronie\u2019s disease. J Urol. 2013;190:2194\u20139.","journal-title":"J Urol"},{"key":"800_CR49","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1111\/jsm.12312","volume":"10","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Hellstrom WJ, McMahon CG, et al. Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie\u2019s disease. J Sex Med. 2013;10:2822\u201331.","journal-title":"J Sex Med"},{"key":"800_CR50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2217\/ijr.11.4","volume":"6","author":"AJ Watt","year":"2011","unstructured":"Watt AJ, Hentz VR. Collagenase clostridium histolyticum: a novel nonoperative treatment for Dupuytren\u2019s disease. Int J Clin Rhematol. 2011;6:123\u201333.","journal-title":"Int J Clin Rhematol"},{"key":"800_CR51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199\u2013207.","journal-title":"J Urol"},{"key":"800_CR52","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bju.13096","volume":"116","author":"L Lipshultz","year":"2015","unstructured":"Lipshultz L, Goldstein I, Seftel A, et al. Clinical efficacy of collagenase clostridium histolyticum in the treatment of Peyronie\u2019s disease by subgroups: results from two large, double-blind, randomized, placebo-controlled, phase 3 studies. BJU Int. 2015;116:650\u20136.","journal-title":"BJU Int"},{"issue":"4 Pt 1","key":"800_CR53","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.juro.2015.10.065","volume":"195","author":"MJ Ziegelmann","year":"2016","unstructured":"Ziegelmann MJ, Viers BR, Mcalvany KL, Bailey GC, Savage JB, Trost LW. Restoration of penile function and patient satisfaction with Intralesional collagenase clostridium histolyticum injection for Peyronie\u2019s disease. J Urol. 2016;195(4 Pt 1):1051\u20136.","journal-title":"J Urol"},{"key":"800_CR54","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.urology.2016.04.049","volume":"94","author":"KK Yang","year":"2016","unstructured":"Yang KK, Bennett N. Peyronie's disease and injectable collagenase clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms. Urology. 2016;94:143\u20137.","journal-title":"Urology"},{"issue":"4","key":"800_CR55","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.sxmr.2017.07.005","volume":"5","author":"A Abdel raheem","year":"2017","unstructured":"\u2022 Abdel raheem A, Johnson M, Abdel-raheem T, Capece M, Ralph D. Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease-A Review of the Literature and a New Modified Protocol. Sex Med Rev. 2017;5(4):529\u201335. Prospective study of 53 men with PD treatment with CCH using a modified protocol. The results showed the new shortened protocol to provide similar results compared to standard protocol with a significant decrease in cost and time commitment.","journal-title":"Sex Med Rev"},{"issue":"2","key":"800_CR56","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.urpr.2016.04.005","volume":"4","author":"BH Cordon","year":"2017","unstructured":"\u2022 Cordon BH, Hofer MD, Hutchinson RC, Broderick GA, Lotan Y, Morey AF. Superior cost effectiveness of penile plication vs intralesional collagenase injection for treatment of Peyronie\u2019s disease deformities. Urol Pract. 2017;4(2):118\u201325. A cost analysis was performed comparing CCH and penile plication. The average cost of plication surgery was $3,039 compared to $25,856 for a treatment course of CCH.","journal-title":"Urol Pract"},{"key":"800_CR57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/IJGM.S5495","volume":"2","author":"K Masuko","year":"2009","unstructured":"Masuko K, Murata M, Yudoh K, Kato T, Nakamura H. Anti-inflammatory effects of hyaluronan in arthritis therapy: not just for viscosity. Int J Gen Med. 2009;2:77\u201381.","journal-title":"Int J Gen Med"},{"issue":"2","key":"800_CR58","first-page":"e83","volume":"4","author":"A Zucchi","year":"2016","unstructured":"Zucchi A, Costantini E, Cai T, et al. Intralesional injection of hyaluronic acid in patients affected with Peyronie\u2019s disease: preliminary results from a prospective, multicenter, pilot study. Sex Med. 2016;4(2):e83\u20138.","journal-title":"Sex Med"},{"key":"800_CR59","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","volume":"56","author":"A Palmieri","year":"2009","unstructured":"Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie\u2019s disease. Eur Urol. 2009;56:363\u20139.","journal-title":"Eur Urol"},{"key":"800_CR60","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/j.1464-410X.2010.09331.x","volume":"106","author":"S Chitale","year":"2010","unstructured":"Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie\u2019s disease: results of a prospective randomized controlled doubleblind trial. BJU Int. 2010;106:1352\u20136.","journal-title":"BJU Int"},{"issue":"11","key":"800_CR61","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1111\/jsm.12275","volume":"10","author":"G Hatzichristodoulou","year":"2013","unstructured":"Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie\u2019s disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med. 2013;10(11):2815\u201321.","journal-title":"J Sex Med"},{"issue":"3","key":"800_CR62","doi-asserted-by":"publisher","first-page":"366","DOI":"10.21037\/tau.2016.03.26","volume":"5","author":"E Chung","year":"2016","unstructured":"Chung E. Pro: does shockwave therapy have a place in the treatment of Peyronie\u2019s disease? Transl Androl Urol. 2016;5(3):366\u201370.","journal-title":"Transl Androl Urol."},{"issue":"5","key":"800_CR63","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1111\/j.1743-6109.2012.02677.x","volume":"9","author":"JP Mulhall","year":"2012","unstructured":"Mulhall JP, Hall M, Broderick GA, Incrocci L. Radiation therapy in Peyronie\u2019s disease. J Sex Med. 2012;9(5):1435\u201341.","journal-title":"J Sex Med"},{"issue":"5","key":"800_CR64","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/jsm.12082","volume":"10","author":"E Chung","year":"2013","unstructured":"Chung E, De young L, Solomon M, Brock GB. Peyronie\u2019s disease and mechanotransduction: an in vitro analysis of the cellular changes to Peyronie\u2019s disease in a cell-culture strain system. J Sex Med. 2013;10(5):1259\u201367.","journal-title":"J Sex Med"},{"key":"800_CR65","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/jsm.12400","volume":"11","author":"JI Martinez-Salamanca","year":"2014","unstructured":"\u2022 Martinez-Salamanca JI, Equi A, Moncada I, et al. Acute phase Peyronie\u2019s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med. 2014;11:506\u201315. 55 men underwent 6 months of PTT and were compared to 41 men who underwent no treatment. All men were in the active phase. Men who underwent PTT had a significant improvement in their curvature and erectile function when compared to the control group.","journal-title":"J Sex Med"},{"key":"800_CR66","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/j.1743-6109.2008.00814.x","volume":"5","author":"LA Levine","year":"2008","unstructured":"Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie\u2019s disease: a single-center pilot study. J Sex Med. 2008;5:1468\u201373.","journal-title":"J Sex Med"},{"key":"800_CR67","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/aja.2012.92","volume":"15","author":"AL Levine","year":"2013","unstructured":"Levine AL, Larsen SM. Surgery for Peyronie's disease. Asian J Androl. 2013;15:27\u201334.","journal-title":"Asian J Androl"},{"key":"800_CR68","first-page":"61","volume":"29","author":"KA Ostrowski","year":"2016","unstructured":"Ostrowski KA, Gannon JA, Walsh TJA. Review of the epidemiology and treatment of Peyronie\u2019s disease. Res Rep Urol. 2016;29:61\u201370.","journal-title":"Res Rep Urol"},{"issue":"6","key":"800_CR69","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/S0022-5347(01)68184-9","volume":"158","author":"LA Levine","year":"1997","unstructured":"Levine LA, Lenting EL. A surgical algorithm for the treatment of Peyronie\u2019s disease. J Urol. 1997;158(6):2149\u201352.","journal-title":"J Urol"},{"issue":"3","key":"800_CR70","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/sj.ijir.3900515","volume":"12","author":"LA Levine","year":"2000","unstructured":"Levine LA, Dimitriou RJ. A surgical algorithm for penile prosthesis placement in men with erectile failure and Peyronie's disease. Int J Impot Res. 2000;12(3):147\u201351.","journal-title":"Int J Impot Res"},{"key":"800_CR71","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/sj.ijir.3900390","volume":"11","author":"HO Andrews","year":"1999","unstructured":"Andrews HO, al-Akraa M, Pryor JP, Ralph DJ. The Nesbit operation for congenital curvature of the penis. Int J Impot Res. 1999;11:119\u201322.","journal-title":"Int J Impot Res"},{"key":"800_CR72","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0022-5347(17)36243-2","volume":"149","author":"D Yachia","year":"1993","unstructured":"Yachia D. Corporeal plication for surgical correction of Peyronie\u2019s disease. J Urol. 1993;149:869.","journal-title":"J Urol"},{"key":"800_CR73","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1743-6109.2007.00429.x","volume":"2","author":"WO Brant","year":"2007","unstructured":"Brant WO, Bella AJ, Lue TF. 16-dot procedure for penile curvature. J Sex Med. 2007;2:277\u201380.","journal-title":"J Sex Med"},{"key":"800_CR74","first-page":"151","volume-title":"Peyronie\u2019s disease: a guide to clinical management Totowa, NJ; Humana","author":"LA Levine","year":"2006","unstructured":"Levine LA. Penile straightening with tunica albuginea plication procedure: TAP procedure. In: Levine LA, editor. Peyronie\u2019s disease: a guide to clinical management Totowa, NJ; Humana; 2006. p. 151\u201360."},{"key":"800_CR75","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11255-009-9678-y","volume":"42","author":"S Ding","year":"2010","unstructured":"Ding S, Lu J, Zhang H, et al. A novel modification of tunical plication by plaque thinning: long-term results in treating penile curvature of Peyronie's disease. Int Urol Nephrol. 2010;42:597\u2013602.","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"800_CR76","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/ijir.2017.34","volume":"29","author":"D Papagiannopoulos","year":"2017","unstructured":"Papagiannopoulos D, Phelps J, Yura E, Levine LA. Surgical outcomes from limiting the use of nonabsorbable suture in tunica albuginea plication for Peyronie's disease. Int J Impot Res. 2017;29(6):258\u201361.","journal-title":"Int J Impot Res"},{"key":"800_CR77","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1464-410X.2004.04566.x","volume":"93","author":"C Horst Van Der","year":"2004","unstructured":"Van Der Horst C, Martinez Portillo FJ, Seif C, et al. Treatment of penile curvature with Essed-Schroder tunical plication: aspects of quality of life from the patients\u2019 perspective. BJU Int. 2004;93:105\u20138.","journal-title":"BJU Int"},{"key":"800_CR78","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.urology.2016.02.009","volume":"95","author":"BA Sherer","year":"2016","unstructured":"Sherer BA, Levine LA. Contemporary review of treatment options for Peyronie\u2019s disease. Urology. 2016;95:16\u201324.","journal-title":"Urology"},{"key":"800_CR79","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1111\/j.1743-6109.2008.00941.x","volume":"5","author":"FL Taylor","year":"2008","unstructured":"Taylor FL, Levine LA. Surgical correction of Peyronie\u2019s disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up. J Sex Med. 2008;5:2221\u20138.","journal-title":"J Sex Med"},{"key":"800_CR80","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/j.1743-6109.2011.02370.x","volume":"8","author":"LA Levine","year":"2011","unstructured":"Levine LA. Partial plaque excision and grafting (PEG) for Peyronie\u2019s disease. J Sex Med. 2011;8:1842\u20135.","journal-title":"J Sex Med"},{"key":"800_CR81","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1111\/j.1743-6109.2012.02849.x","volume":"9","author":"J Rybak","year":"2012","unstructured":"Rybak J, Papagiannopoulos D, Levine L. A retrospective comparative study of traction therapy vs. no traction following tunica albuginea plication or partial excision and grafting for Peyronie\u2019s disease: measured lengths and patient perceptions. J Sex Med. 2012;9:2396\u2013403.","journal-title":"J Sex Med"},{"key":"800_CR82","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0090-4295(03)00244-9","volume":"62","author":"MF Usta","year":"2003","unstructured":"Usta MF, Bivalacqua TJ, Sanabria J, Koksal IT, Moparty K, Hellstrom WJG. Patient and partner satisfaction and long-term results after surgical treatment for Peyronie's disease. Urology. 2003;62:105\u20139.","journal-title":"Urology"},{"key":"800_CR83","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/S0022-5347(05)67525-8","volume":"163","author":"F Montorsi","year":"2000","unstructured":"Montorsi F, Salonia A, Maga T, et al. Evidence based assessment of long-term results of plaque incision and vein grafting for Peyronie's disease. J Urol. 2000;163:1704\u20138.","journal-title":"J Urol"},{"key":"800_CR84","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0022-5347(17)32519-3","volume":"152","author":"SK Wilson","year":"1994","unstructured":"Wilson SK, Delk JR. A new treatment for Peyronie\u2019s disease: modeling the penis over an inflatable penile prosthesis. J Urol. 1994;152:1121\u20133.","journal-title":"J Urol"},{"issue":"4","key":"800_CR85","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.eururo.2006.10.027","volume":"51","author":"DK Montague","year":"2007","unstructured":"Montague DK. Penile prosthesis implantation: size matters. Eur Urol. 2007;51(4):887\u20138.","journal-title":"Eur Urol"},{"issue":"9","key":"800_CR86","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1111\/j.1743-6109.2012.02675.x","volume":"9","author":"L Rolle","year":"2012","unstructured":"Rolle L, Ceruti C, Timpano M, Sedigh O, Destefanis P, Galletto E, et al. A new, innovative, lengthening surgical procedure for Peyronie\u2019s disease by penile prosthesis implantation with double dorsal-ventral patch graft: the \u201csliding technique\u201d. J Sex Med. 2012;9(9):2389\u201395.","journal-title":"J Sex Med"},{"issue":"6","key":"800_CR87","first-page":"1822","volume":"195","author":"AF Morey","year":"2016","unstructured":"\u2022 Morey AF. Re: Penile lengthening and widening without grafting according to a modified \u2018sliding\u2019 technique. J Urol. 2016;195(6):1822\u20133. A modified sliding technique was performed on 143 patients to determine the feasibility and safety of this length and girth restoring procedure. The authors reported a mean length gain of 3.1 cm.","journal-title":"J Urol"},{"key":"800_CR88","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.urology.2017.06.020","volume":"107","author":"SK Wilson","year":"2017","unstructured":"\u2022 Wilson SK, Mora-estaves C, Egydio P, et al. Glans necrosis following penile prosthesis implantation: prevention and treatment suggestions. Urology. 2017;107:144\u20138. Examined 21 patients who had glans necrosis following penile prosthesis implantation to better determine the etiology. Risk factors for glans necrosis include cardiovascular disease, diabetes, using sliding technique, and subcoronal incision.","journal-title":"Urology"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-018-0800-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-018-0800-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-018-0800-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T19:34:14Z","timestamp":1558035254000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-018-0800-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,17]]},"references-count":88,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["800"],"URL":"https:\/\/doi.org\/10.1007\/s11934-018-0800-5","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,17]]},"assertion":[{"value":"17 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Edward Capoccia declares no potential conflicts of interest.Laurence A. Levine reports consultant and speaker fees from Boston Scientific and Coloplast.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}],"article-number":"51"}}